Schneider Joachim
Institut und Poliklinik für Arbeits- und Sozialmedizin der Justus-Liebig Universität, Aulweg 129/III, D-35385 Giessen, Germany.
Adv Clin Chem. 2006;42:1-41. doi: 10.1016/s0065-2423(06)42001-1.
The expression of biomarkers by lung cancers is useful in the diagnosis and clinical management of patients with lung cancer. Biomarkers provide insight into histogenesis, interrelationships, and biological behavior of lung tumors. This chapter presents data on lung cancer detection, involving some of the most studied and interesting lung cancer biomarkers to date-CYFRA 21-1, NSE, ProGRP, SCC, CEA, Tumor M2-PK, as well as markers in clinical application such as CRP, LDH, tumor-suppressor genes and oncogenes, CA125, CgA, NCAM, and TPA. Biomarker profiles in combination with fuzzy logic techniques have also been addressed. Serum markers used alone or in combination with other indices might play an important role in monitoring response to therapy in early detection of tumor reactivation in new treatment strategies as well as in secondary prevention.
肺癌生物标志物的表达对肺癌患者的诊断和临床管理具有重要意义。生物标志物有助于深入了解肺肿瘤的组织发生、相互关系及生物学行为。本章介绍了肺癌检测的数据,涉及一些迄今为止研究最多且最受关注的肺癌生物标志物——细胞角蛋白19片段(CYFRA 21-1)、神经元特异性烯醇化酶(NSE)、胃泌素释放肽前体(ProGRP)、鳞状细胞癌抗原(SCC)、癌胚抗原(CEA)、肿瘤M2丙酮酸激酶(Tumor M2-PK),以及临床应用中的标志物,如C反应蛋白(CRP)、乳酸脱氢酶(LDH)、肿瘤抑制基因和癌基因、癌抗原125(CA125)、嗜铬粒蛋白A(CgA)、神经细胞黏附分子(NCAM)和组织多肽抗原(TPA)。还探讨了结合模糊逻辑技术的生物标志物谱。单独使用或与其他指标联合使用的血清标志物,在新治疗策略中监测肿瘤复发的早期检测以及二级预防中对治疗反应的监测方面可能发挥重要作用。